Synthetic Biologics (SYN) Scheduled to Post Earnings on Wednesday

Share on StockTwits

Synthetic Biologics (NYSEAMERICAN:SYN) will post its quarterly earnings results after the market closes on Wednesday, May 5th. Investors interested in participating in the company’s conference call can do so using this link.

Synthetic Biologics (NYSEAMERICAN:SYN) last released its quarterly earnings data on Wednesday, March 3rd. The company reported ($0.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.06).

Shares of NYSEAMERICAN SYN traded down $0.03 during mid-day trading on Tuesday, hitting $0.51. 9,231 shares of the company’s stock traded hands, compared to its average volume of 18,267,070. Synthetic Biologics has a 1 year low of $0.25 and a 1 year high of $1.70. The company’s 50-day moving average is $0.37 and its two-hundred day moving average is $0.38. The company has a market capitalization of $65.54 million, a P/E ratio of -0.75 and a beta of 2.29.

Separately, Maxim Group upgraded Synthetic Biologics from a “hold” rating to a “buy” rating in a research report on Thursday, March 18th.

Synthetic Biologics Company Profile

Synthetic Biologics, Inc, a clinical-stage company, develops therapeutics to treat gastrointestinal (GI) diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in GI tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases.

Featured Story: What is Cost of Debt?

Earnings History for Synthetic Biologics (NYSEAMERICAN:SYN)

Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with's FREE daily email newsletter.